Author:
Li Jinyin,Fang Jing,Zhong Fanyi,Li Wenxue,Tang Yuanjun,Xu Yungen,Mao Shilong,Fan Guorong
Funder
Shanghai Key Laboratory for Pharmaceutical Metabolites Research
Ministry of Science and Technology of PR China
China Pharmaceutical University
Subject
Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry
Reference26 articles.
1. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin;Eisert;Arterioscler. Thromb. Vasc. Biol.,2010
2. Structure-based design of novel potent nonpeptide thrombin inhibitors;Hauel;J. Med. Chem.,2002
3. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis;Wienen;J. Thromb. Haemost.,2007
4. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders;Cheng;Clin. Ther.,2012
5. Influence of renal Impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study;Strangier;Clin. Pharmacokinet.,2010
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献